Rosen Comments on Korean Pharma Companies Doing Business in the U.S.
18 April 2019
Korea Biomedical Review
Partner David Rosen was quoted in a Korea Biomedical Review article, “How Korean pharma companies can succeed in US,” about how Korean pharmaceutical and biosimilar companies can find success in America.
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
Rosen, speaking at BIO KOREA 2019, said it is essential for Korean companies to develop drugs with a sense of responsibility for making the products safe. He also said if such expectations are not met, the companies can receive sanctions and penalties, including regulatory enforcement action, civil monetary penalties, and criminal liability.
“Import detention is something that everyone should be afraid the most as the Food and Drug Administration can block any import of the product,” he said. “Therefore, companies have to respond to all warning letters and the concerns that the FDA has, and address them.”
People
Related News
20 September 2024
In the News
David Rosen Featured for Insight on Looming FDA Final Rule for Cosmetic Manufacturing
Foley & Lardner LLP partner David Rosen is featured by CosmeticsDesign for his insights on the U.S. Food and Drug Administration's final rule establishing Good Manufacturing Practices for the cosmetics industry in the article, "Preparing for MoCRA’s 2025 cGMP deadline: What cosmetic manufacturers and suppliers need to know."
19 September 2024
In the News
Patrick Daugherty on UChicago's Desk Reference for Crypto, Web3 – 'This is very much for lawyers'
Foley & Lardner LLP partner Patrick Daugherty commented on the University of Chicago Law School's recently released open-access legal desk reference on crypto and Web3 matters in the Law.com article, "UChicago Law Professors Release Desk Reference Breaking Down Crypto, Web 3 for Attorneys."
18 September 2024
In the News
Eli Mazour Talks Patents on IPWatchdog Unleashed Podcast
Foley & Lardner of counsel Eli Mazour appeared on the IPWatchdog Unleashed podcast episode, "Problems, Solutions and the Case for Patents," to discuss patents and innovation, the Federal Circuit, the value of patents to clients, and patent strategy.